Transpire Bio Manufacturing Facility Receives the Establishment Inspection Report Following a Pre-Approval Inspection by the U.S. FDA
SUNRISE, Fla., Dec. 09, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that the U.S. FDA has completed a Pre-Approval Inspection (PAI) at its manufacturing facility in Weston, Florida, with a Voluntary Action Indicated (VAI) classification. The company has now […]
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
News US-Based Manufacturing US-Based Manufacturing TRB-ILD1 granted U.S. Orphan Drug Designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF) TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) SUNRISE, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused […]
Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
News SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate and vilanterol inhalation powder, a generic version of Breo® Ellipta®1 100/25, has been accepted for filing by the U.S. […]
Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor
News Transpire Bio Enters into Exclusive License Agreement with Suzhou Intragrand Pharma for Investigational PDE4 Inhibitor WESTON, Jun 03, 2025 (GLOBE NEWSWIRE) — Transpire Bio Inc., a U.S.-based, integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has signed an exclusive license agreement with Suzhou Intragrand […]
Transpire Bio Announces R&D and Manufacturing Expansion
SUNRISE, Fla., May 06, 2025 (GLOBE NEWSWIRE) — Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has signed an agreement to expand the footprint of its R&D and Manufacturing capabilities in Pembroke Pines, Florida. The expansion is expected to enhance and build upon […]
Transpire Bio Announces Progress in Clinical Development with Initiation of a New Human Subject Study for Asthma and COPD Inhaled Drug Program
News WESTON, Fla., Jan. 13, 2024 (GLOBE NEWSWIRE) Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the commencement of a new human subject study for its inhalation therapy program targeting asthma and chronic obstructive pulmonary disease (COPD). This advancement builds on the promising results from a previous clinical […]
Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine
News Transpire Bio announces agreement with Recipharm for the development of an inhaled medicine WESTON, Fla., July 7, 2025 (GLOBE NEWSWIRE) — Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has announced a definitive agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment […]
Transpire Bio Achieves Important Corporate Milestone with Dosing of First Human Subject in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program
News Transpire Bio Achieves Important Corporate Milestone with Dosing of First Human Subject in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program WESTON, Fla., Dec 17, 2024 (GLOBE NEWSWIRE) Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a definitive agreement with […]
Transpire Bio Announces Corporate Office Expansion
News WESTON, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has signed an agreement to expand the footprint of its global headquarters in South Florida. The expansion is expected to accommodate additional executive leadership and administrative […]
Transpire Bio Strengthens Its Leadership Team with a New Senior-Level Appointment
News Transpire Bio Strengthens Its Leadership Team with a New Senior-Level Appointment WESTON, Fla., July 7, 2025 (GLOBE NEWSWIRE) — Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced the addition of another senior-level inhalation expert to their leadership team, filling a key position. Dr. […]